R-348 CHOLINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C23H21FN5O4S.C5H14NO
Molecular Weight	586.678
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[N+](C)(C)CCO.CCC(=O)[N-]S(=O)(=O)C1=CC(NC2=NC(NC3=CC=C(OCC#C)C=C3)=C(F)C=N2)=CC=C1C

InChI

InChIKey=LZMBOMHVTNXZSS-UHFFFAOYSA-M

InChI=1S/C23H22FN5O4S.C5H14NO/c1-4-12-33-18-10-8-16(9-11-18)26-22-19(24)14-25-23(28-22)27-17-7-6-15(3)20(13-17)34(31,32)29-21(30)5-2;1-6(2,3)4-5-7/h1,6-11,13-14H,5,12H2,2-3H3,(H3,25,26,27,28,29,30);7H,4-5H2,1-3H3/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	C23H22FN5O4S
Molecular Weight	483.515
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C5H13NO
Molecular Weight	103.1628
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Approval Year

Substance Class	Chemical Created by `admin` on `Sat Dec 16 12:04:38 UTC 2023` Edited by `admin` on `Sat Dec 16 12:04:38 UTC 2023`
Record UNII	02STA794M3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

R-348 CHOLINE

Common Name

English

ETHANAMINIUM, 2-HYDROXY-N,N,N-TRIMETHYL-, SALT WITH N-((5-((5-FLUORO-4-((4-(2-PROPYN-1-YLOXY)PHENYL)AMINO)-2-PYRIMIDINYL)AMINO)-2-METHYLPHENYL)SULFONYL)PROPANAMIDE (1:1)

Systematic Name

English

N-(5-((5-FLUORO-4-(4-PROP-2-YNOXYANILINO)PYRIMIDIN-2-YL)AMINO)-2-METHYL-PHENYL)SULFONYLPROPANAMIDE; 2-(TRIMETHYL-$L^5-AZANYL)ETHANOL

Systematic Name

English

R-348 CHOLINE SALT

Common Name

English

R-932348 CHOLINE SALT

Common Name

English

Code System Code Type Description

PUBCHEM

121596578

Created by admin on Sat Dec 16 12:04:38 UTC 2023 , Edited by admin on Sat Dec 16 12:04:38 UTC 2023

PRIMARY

CAS

1620142-65-5

Created by admin on Sat Dec 16 12:04:38 UTC 2023 , Edited by admin on Sat Dec 16 12:04:38 UTC 2023

PRIMARY

FDA UNII

02STA794M3

Created by admin on Sat Dec 16 12:04:38 UTC 2023 , Edited by admin on Sat Dec 16 12:04:38 UTC 2023

PRIMARY

Related Record Type Details


					3J396119JY

R-348

ACTIVE MOIETY

Comments:

But fostamatinib was always the company's primary RA play, and in 2012 Rigel moved R348 also referred to as R-932348 into a phase I study in 36 patients with mild to moderate dry eye. Findings showed the drug was well tolerated, and in May 2013 Rigel decided to move the wholly owned compound into phase II development. Rigel Pharmaceuticals Inc. left open the tiniest prospect for success for dry eye candidate R348 after the Janus kinase/spleen tyrosine kinase (JAK/SYK) inhibitor missed both primary and secondary endpoints in a phase II study.